give an outline on mendelian disorders, autosomal dominant/recessive, x-linked dominant/recessive w.r.t. Robbins and Cotran pathology

Reading File

Finding Sources

Reading File

I now have comprehensive material from Robbins & Cotran. Let me compile the full detailed outline.

Mendelian Disorders — Outline per Robbins, Cotran & Kumar: Pathologic Basis of Disease

I. Overview: Categories of Human Genetic Disease

Genetic disorders are broadly grouped into three categories:

Monogenic (Mendelian) Disorders — single-gene mutations with large effects; highly penetrant; follow classic Mendelian inheritance (autosomal dominant, autosomal recessive, X-linked).
Chromosomal Disorders — structural or numerical alterations affecting autosomes or sex chromosomes; often arise de novo in the germline.
Complex Multigenic (Multifactorial) Disorders — multiple genetic variants + environmental factors (e.g., atherosclerosis, diabetes, hypertension).

A fourth category of somatically acquired mutations (driving clonal hematopoiesis, cancers, overgrowth syndromes) is also increasingly recognized.

II. Mutations Underlying Mendelian Disorders

Mutations are permanent changes in DNA sequence. Key types:

Type	Mechanism	Example
Point mutation	Single nucleotide substitution	Missense → altered amino acid; Nonsense → premature stop codon
Frameshift	Insertion or deletion of non-multiples of 3 bases	4-bp insertion in HEXA → Tay-Sachs disease
Trinucleotide repeat expansions	Expansion of repetitive sequences	Fragile X, Huntington
Deletions/duplications	Larger DNA copy number changes	Affects gene dosage

Functional Consequences of Mutations

Loss-of-function: enzyme/transport protein deficiencies (usually AR)
Gain-of-function: constitutively active or toxic protein products (usually AD)

Key Concepts

Pleiotropism: one mutation → many end-organ effects (e.g., sickle cell anemia: hemolysis + vascular occlusion + splenic fibrosis + bone changes)
Genetic heterogeneity: different gene loci → same phenotype (e.g., congenital deafness)

III. Transmission Patterns of Single-Gene Disorders

A. Autosomal Dominant (AD) Disorders

Fundamental Rules:

Manifested in the heterozygous state
Both males and females are equally affected and can transmit
Affected parent → 50% chance each child is affected
Vertical transmission through generations

Exceptions and Modifiers:

Concept	Definition
De novo mutation	No affected parent; propensity for new mutations in germ cells of older fathers (e.g., FGFR2/FGFR3 mutations → Apert syndrome, achondroplasia)
Incomplete penetrance	Mutant gene carried but disease not expressed (e.g., 50% penetrance = 50% carrying the gene are affected)
Variable expressivity	Trait present in all carriers but at differing severity
Anticipation	Earlier onset and increasing severity in successive generations (e.g., trinucleotide repeat disorders)

Biochemical Mechanisms in AD Disorders:

Loss of regulatory proteins (e.g., tumor suppressors) — one mutant allele reduces the gene product sufficiently to alter function
Gain-of-function — mutant protein acquires new toxic activity
Dominant-negative effect — mutant product interferes with normal allele product (common with structural proteins like collagen and fibrillin)

Examples of AD Disorders (Table 5.1):

System	Disorder
Neurologic	Huntington disease, neurofibromatosis, myotonic dystrophy
Urologic	Adult polycystic kidney disease
Cardiovascular	Familial hypercholesterolemia, hereditary hemorrhagic telangiectasia
Hematopoietic	Hereditary spherocytosis, von Willebrand disease
Skeletal	Marfan syndrome, Ehlers-Danlos syndrome (some variants), achondroplasia
Metabolic	Familial hypercholesterolemia

Featured AD Disorder — Marfan Syndrome:

Gene: FBN1 (fibrillin-1), chromosome 15q21
Fibrillin-1 is an extracellular glycoprotein → component of microfibrils in connective tissue
Mutations disrupt elastin meshworks and cause excess release of TGF-β from ECM (unopposed TGF-β signaling → tissue remodeling)
Morphology:
- Skeletal: tall stature, dolichocephaly, arachnodactyly, hypermobile joints, pectus excavatum/carinatum, kyphoscoliosis
- Ocular: bilateral ectopia lentis (upward/outward lens subluxation) — a near-pathognomonic sign
- Cardiovascular: mitral valve prolapse (40–50%), medial degeneration of aorta → aortic dilation, aortic regurgitation, aortic dissection (most common cause of death)

B. Autosomal Recessive (AR) Disorders

Fundamental Rules:

Disease manifests only in the homozygous state (both alleles mutated)
Heterozygous carriers are phenotypically normal
Both parents are typically carriers (heterozygotes)
25% chance of affected offspring per pregnancy; 50% carriers; 25% normal
Often presents in siblings, not parents ("horizontal" pedigree pattern)
More common when parents are consanguineous

Key Features Distinguishing AR from AD:

Expression is more uniform (less variable expressivity)
Complete penetrance is more common
Onset often in early childhood (enzyme deficiencies manifest when both alleles are absent)
Enzyme deficiency is the predominant mechanism — 50% residual enzyme from one functional allele is usually sufficient (hence carriers are unaffected)

Examples of AR Disorders (Table 5.2):

System	Disorder
Metabolic	Cystic fibrosis, phenylketonuria, galactosemia, homocystinuria, lysosomal storage diseases, α₁-antitrypsin deficiency, Wilson disease, hemochromatosis, glycogen storage diseases
Hematopoietic	Sickle cell anemia, thalassemias
Endocrine	Congenital adrenal hyperplasia
Skeletal	Ehlers-Danlos syndrome (some variants), alkaptonuria
Nervous	Spinal muscular atrophy, Friedreich ataxia, neurogenic muscular atrophies

Featured AR Disorder — Lysosomal Storage Diseases (prototype of AR enzyme deficiency):

Inherited deficiency of lysosomal enzymes → incomplete catabolism → accumulation of insoluble intermediates within lysosomes
Pathogenic consequences:
1. Primary accumulation — engorged lysosomes interfere with cell function
2. Defective autophagy — impaired mitophagy → dysfunctional mitochondria persist → free radical generation → intrinsic apoptosis
3. Secondary accumulation — aggregation-prone proteins (α-synuclein, Huntingtin) accumulate
~70 lysosomal storage diseases identified; frequency ~1 in 5000 live births
Treatment approaches: (1) Enzyme replacement / gene therapy; (2) Substrate reduction therapy; (3) Molecular chaperone therapy

C. X-Linked Disorders

General Principles:

Caused by mutations in genes on the X chromosome; males are hemizygous (no corresponding Y-linked locus to compensate)
Y chromosome male-specific region encodes few genes (mostly spermatogenesis); Y-linked mutations → male infertility → cannot be transmitted

C1. X-Linked Recessive (XLR) Disorders

Fundamental Rules:

Males are predominantly affected (hemizygous — one mutant X is sufficient for disease)
Females are typically carriers (heterozygous); generally unaffected because of the normal allele
An affected male does not transmit disorder to sons (sons inherit Y chromosome from father); all daughters of an affected male are obligate carriers
Sons of heterozygous women: 50% affected; daughters: 50% carriers

Lyon Hypothesis (X-Inactivation):

In females, one X chromosome is randomly inactivated in each somatic cell → females are mosaics
In most carriers, random inactivation results in ~50% cells with the normal X active → no disease
If X-inactivation is skewed to favor inactivation of the wild-type allele → manifesting carrier female

Examples of XLR Disorders (Table 5.3):

System	Disorder
Musculoskeletal	Duchenne muscular dystrophy
Hematopoietic	Hemophilia A and B, chronic granulomatous disease, G6PD deficiency
Immune	Agammaglobulinemia (Bruton), Wiskott-Aldrich syndrome
Metabolic	Diabetes insipidus (nephrogenic), Lesch-Nyhan syndrome
Nervous	Fragile X syndrome

Featured XLR Disorder — G6PD Deficiency:

X-linked; enzyme deficiency → episodic hemolytic anemia triggered by infection or oxidant drugs
Expressed principally in males; rare manifesting carrier females result from skewed X-inactivation

C2. X-Linked Dominant (XLD) Disorders

Fundamental Rules:

Rare; caused by dominant mutations on X chromosome
Heterozygous females are affected (unlike XLR where females are carriers)
Affected males tend to be more severely affected than females, or the condition may be lethal in males (e.g., incontinentia pigmenti)
Transmission: affected mother → 50% daughters affected, 50% sons affected; affected father → all daughters affected, no sons affected

Examples:

Fragile X syndrome (technically complex — trinucleotide expansion, discussed separately under non-classic inheritance)
Incontinentia pigmenti (IKBKG/NEMO mutations) — lethal in males, affects females with skin, eye, neurologic, and dental abnormalities
Rett syndrome (MECP2 mutations) — predominantly affects females
X-linked hypophosphatemia (PHEX mutations) — rickets, affects both sexes but females less severely

IV. Comparing the Four Inheritance Patterns at a Glance

Feature	AD	AR	XLR	XLD
State in which disease appears	Heterozygous	Homozygous	Hemizygous (males)	Heterozygous (females) + hemizygous (males)
Sex affected	Both equally	Both equally	Males >> Females	Both; females may be less severely affected
Carrier state	Not applicable	Heterozygotes	Heterozygous females	Not applicable (heterozygotes are affected)
Father → son transmission	Yes	Yes	No	No (sons get Y)
Risk to offspring of carrier	50% affected	25% affected, 50% carriers	Sons 50% affected; daughters 50% carriers	50% children affected
Variable expressivity	Common	Less common	Common	Variable
New mutations	Common	Rare	Occasional	Occasional
Key molecular mechanism	Gain-of-function / dominant-negative / haploinsufficiency	Enzyme deficiency	Enzyme/protein deficiency (hemizygous)	Dominant gain- or loss-of-function on X

V. Selected Specific Diseases Covered in Detail by Robbins & Cotran

Disorder	Inheritance	Gene/Defect
Marfan syndrome	AD	FBN1 (fibrillin-1) — TGF-β excess
Familial hypercholesterolemia	AD	LDLR (LDL receptor) loss-of-function
Huntington disease	AD	HTT CAG repeat expansion
Neurofibromatosis type 1	AD	NF1 (neurofibromin)
Cystic fibrosis	AR	CFTR — defective Cl⁻ channel
Phenylketonuria	AR	PAH (phenylalanine hydroxylase) deficiency
Sickle cell anemia	AR	HBB — Glu→Val substitution at position 6
Tay-Sachs disease	AR	HEXA — 4-bp insertion → frameshift → absent hexosaminidase A
Gaucher disease	AR	GBA (glucocerebrosidase) deficiency
α₁-Antitrypsin deficiency	AR	SERPINA1 — misfolded protein accumulation in liver + uninhibited elastase in lungs
Duchenne muscular dystrophy	XLR	DMD (dystrophin) — frameshift deletions → absent dystrophin
Hemophilia A	XLR	F8 (Factor VIII) deficiency
G6PD deficiency	XLR	G6PD — oxidant-induced hemolysis
Fragile X syndrome	XLD/complex	FMR1 — CGG trinucleotide repeat expansion

VI. Exceptions and Departures from Classic Mendelian Inheritance

Robbins & Cotran also highlights non-classic patterns that are covered in the same chapter:

Trinucleotide repeat disorders (anticipation) — Huntington, myotonic dystrophy, Fragile X
Genomic imprinting — Prader-Willi (paternal 15q11-q13 deletion) vs. Angelman syndrome (maternal deletion same region)
Mitochondrial inheritance — maternally transmitted; affects organs with high energy demand
Mosaicism — somatic or germline; explains variable expressivity
Uniparental disomy — both copies of a chromosome derived from one parent

Source: Robbins, Cotran & Kumar — Pathologic Basis of Disease (ISBN 9780443264528), Chapter 5: Genetic Disorders, pp. 139–165

tutorial on microcytic and macrocytic anemia

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

I have all the content needed for a comprehensive tutorial. Let me now compose the full tutorial.

Tutorial: Microcytic & Macrocytic Anemias

Based on Robbins & Kumar Basic Pathology and Robbins, Cotran & Kumar Pathologic Basis of Disease

Conceptual Framework: Classifying Anemia by MCV

MCV	Category	Key Causes
< 80 fL	Microcytic	Iron deficiency, thalassemia, anemia of chronic disease, sideroblastic anemia
80–100 fL	Normocytic	Hemolytic anemias, aplastic anemia, acute blood loss
> 100 fL	Macrocytic	Megaloblastic (B12/folate deficiency), non-megaloblastic (liver disease, hypothyroidism, drugs)

PART I — MICROCYTIC ANEMIAS (MCV < 80 fL)

The unifying pathophysiology is impaired hemoglobin synthesis, affecting heme (iron deficiency, sideroblastic), globin (thalassemia), or both.

1. Iron Deficiency Anemia (IDA)

Epidemiology: The most common nutritional deficiency worldwide. ~10% of people in high-resource countries and 25–50% in low-resource countries are anemic, with IDA the leading cause.

Iron Metabolism (Essential Background)

Total body iron: ~3.5 g (men) / ~2.5 g (women)
Functional pool (80%): Hemoglobin, myoglobin, iron-containing enzymes (catalase, cytochromes)
Storage pool (15–20%): Ferritin and hemosiderin in liver macrophages, spleen, and bone marrow

Parameter	Normal value
Serum iron	~120 µg/dL (men), ~100 µg/dL (women)
Transferrin saturation	~33%
TIBC	300–350 µg/dL
Dietary iron (Western diet)	10–20 mg/day
Daily iron loss	1–2 mg/day (mucosal/skin cell shedding)

Iron absorption pathway (duodenum):

Fe³⁺ → Fe²⁺ via duodenal cytochrome B (ferric reductase)
Fe²⁺ enters enterocyte via DMT-1 (divalent metal transporter-1)
Fe²⁺ exits basolateral membrane via ferroportin
Reoxidised to Fe³⁺ by hephaestin/ceruloplasmin → binds transferrin

Hepcidin: A liver-secreted peptide that negatively regulates ferroportin. Iron levels are sensed by HFE protein on hepatocytes → rising iron → rising hepcidin → less ferroportin → less absorption. Hepcidin is also upregulated by IL-6 (inflammation) and downregulated by erythroferrone (from erythroblasts during active erythropoiesis).

Causes of IDA

Setting	Cause
High-resource countries	Chronic blood loss — GI tract (peptic ulcer, colon cancer, hemorrhoids); female genital tract (menorrhagia)
Low-resource countries	Inadequate intake — vegetarian diets, low bioavailability
Universal	Increased demand — pregnancy, infancy
Malabsorption	Celiac disease, gastritis, post-gastrectomy

Stages of Iron Deficiency (in sequence)

Depletion of iron stores → ↓ serum ferritin, absent bone marrow iron staining; no anemia yet
Iron-limited erythropoiesis → ↓ serum iron, ↑ TIBC, ↓ transferrin saturation
Frank IDA → microcytic hypochromic anemia, ↑ erythropoietin (marrow response blunted by iron lack)

Morphology

Iron deficiency anemia peripheral blood smear showing microcytic hypochromic red cells with increased central pallor

Fig. 10.10 — Iron deficiency anemia peripheral smear: microcytic, hypochromic red cells with increased central pallor. Scattered fully haemoglobinised cells from a recent transfusion appear darker. (Robbins Basic Pathology)

Microcytic, hypochromic RBCs (MCV ↓, MCH ↓, MCHC ↓)
Increased central pallor (>1/3 of cell diameter)
Anisocytosis + poikilocytosis
Platelets often elevated (reactive thrombocytosis)
Reticulocyte count: normal or slightly low (response blunted)

Lab Findings Summary

Test	IDA	ACD	Thalassemia trait
Serum iron	↓	↓	Normal
Ferritin	↓	↑	Normal/↑
TIBC	↑	↓	Normal
Transferrin saturation	↓	↓	Normal
RBC count	↓	↓	↑ or normal
RDW	↑	Normal	Normal/↑

Clinical Features

Often mild and asymptomatic
Weakness, listlessness, pallor in severe cases
Long-standing: koilonychia (spoon nails), thin/flat nails
Pica — compulsion to eat non-food items (dirt, clay, ice/pagophagia) — a neurobehavioral complication
Angular cheilitis, glossitis (sore tongue)
Impaired cognitive performance and reduced immunocompetence

"Persons often die with iron deficiency anemia but virtually never of it. Microcytic hypochromic anemia is not a disease but a symptom — always investigate the underlying cause." — Robbins Basic Pathology

2. Anemia of Chronic Disease (ACD) / Anemia of Inflammation

A functional iron deficiency — iron is abundant but sequestered and unavailable for erythropoiesis.

Common underlying conditions:

Chronic infections: osteomyelitis, bacterial endocarditis, lung abscess
Chronic immune disorders: rheumatoid arthritis, Crohn disease
Cancers: Hodgkin lymphoma, lung/breast carcinoma

Pathogenesis: Pro-inflammatory cytokines (especially IL-6) → ↑ hepatic hepcidin → hepcidin downregulates ferroportin on marrow macrophages → iron is trapped in macrophages and cannot be delivered to erythroblasts. Additionally, chronic inflammation blunts renal erythropoietin synthesis.

Key distinguishing lab feature:

Serum iron: ↓ (same as IDA)
Ferritin: ↑ (iron sequestered, not depleted) — key differentiator
TIBC: ↓ (unlike IDA where TIBC is ↑)
Red cells: mildly hypochromic and microcytic or normocytic

Treatment: Treat the underlying condition; erythropoietin + iron can temporarily improve anemia.

3. Thalassemias

Definition: Inherited disorders of globin chain synthesis causing reduced (or absent) production of α- or β-globin chains.

Genetics:

β-globin gene: single gene on chromosome 11 (mutations = mainly point mutations affecting transcription, splicing, or translation of β-globin mRNA)
α-globin genes: two tandem genes on chromosome 16 per haploid genome (4 total; mutations = mainly gene deletions)
Autosomal codominant inheritance

Pathogenesis: Reduced globin synthesis → (1) hemoglobin deficiency → microcytic hypochromic anemia; (2) excess unpaired globin chains precipitate → intracellular inclusions → RBC membrane damage → hemolysis and ineffective erythropoiesis.

β-Thalassemia

Syndrome	Genotype	Clinical Features
β-Thalassemia major (Cooley anemia)	β⁰/β⁰ (no β-chain)	Severe transfusion-dependent anemia; splenomegaly; growth retardation; extramedullary hematopoiesis; facial bone changes ("chipmunk face"); iron overload
β-Thalassemia intermedia	β⁺/β⁰ or β⁺/β⁺	Moderately severe; transfusions not required
β-Thalassemia minor (trait)	β⁺/β (one normal allele)	Asymptomatic; mild/absent anemia; ↑ HbA2; often mistaken for IDA — MCV low but RBC count high

α-Thalassemia

Syndrome	Gene deletions	Clinical Features
Silent carrier	1 deleted (−/α, α/α)	No abnormality; asymptomatic
α-Thalassemia trait	2 deleted	Asymptomatic; resembles β-thal minor
HbH disease	3 deleted (−/−, −/α)	Moderate anemia (resembles β-thal intermedia); HbH (β₄ tetramers)
Hydrops fetalis	4 deleted (−/−, −/−)	Lethal in utero; Hb Bart's (γ₄ tetramers); incompatible with extrauterine life

Key point: Thalassemia trait is commonly misdiagnosed as IDA — distinguish by: normal/↑ ferritin, normal/↑ TIBC, ↑ RBC count, ↑ HbA2 on HPLC (in β-thal minor).

4. Sideroblastic Anemia

Defining lesion: Ringed sideroblasts — abnormal erythroid precursors in which iron-laden mitochondria form a perinuclear ring (seen on Prussian blue stain of bone marrow).

Mechanism: Disruption of heme synthesis → iron cannot be incorporated into protoporphyrin → accumulates in mitochondria around the nucleus.

Types:

Form	Cause
Inherited (X-linked)	Mutations in ALAS2 gene (ALA synthase 2 — first step of heme synthesis)
Inherited (AR)	Mutations in SLC25A38 (glycine importer)
Acquired — MDS	Myelodysplastic syndrome (most common acquired form)
Acquired — drugs/toxins	Ethanol, isoniazid, pyrazinamide, linezolid
Acquired — nutritional	Copper deficiency (also zinc excess)

Clinical: Microcytic anemia in inherited forms; dimorphic RBC population (microcytic + normocytic/macrocytic mix) in acquired forms. Copper deficiency also causes myelopathy.

Treatment: Pyridoxine (vitamin B6) for ALAS2 mutations (some respond); discontinue offending drug for acquired forms; treat underlying MDS.

PART II — MACROCYTIC ANEMIAS (MCV > 100 fL)

Divided into megaloblastic and non-megaloblastic types.

Megaloblastic Anemias

Common theme: Impaired DNA synthesis → nuclear-cytoplasmic asynchrony → ineffective hematopoiesis.

Pathogenesis: Vitamin B12 and folate are required for synthesis of thymidine (one of the four DNA bases). Deficiency → defective DNA replication → rapidly dividing cells most affected (marrow, GI epithelium). Two consequences:

Many progenitors trigger DNA damage response → apoptosis (ineffective erythropoiesis)
Surviving progenitors produce fewer, larger red cells (fewer cell divisions → larger cells)

Universal Morphologic Features of Megaloblastic Anemia

Macro-ovalocytes (large, oval RBCs without central pallor — hyperchromic appearance, but MCHC is not truly elevated)
Marked anisocytosis and poikilocytosis
Hypersegmented neutrophils (5+ lobes in a single neutrophil, or ≥1 neutrophil with 6+ lobes) — pathognomonic
Low reticulocyte count
Hypercellular bone marrow with megaloblastic changes: giant bands, giant metamyelocytes, large erythroid precursors with immature-appearing ("open") nuclei relative to mature cytoplasm

5. Folate Deficiency Anemia

Sources of folate: Green leafy vegetables, liver, dairy. Heat-labile (destroyed by cooking).

Body stores: Only 5–20 mg total; sufficient for only 3–4 months — deficiency develops quickly.

Causes of folate deficiency:

Category	Examples
Decreased intake	Poor diet, alcoholism (most common in high-resource countries), infancy
Impaired absorption	Malabsorption, intrinsic intestinal disease, anticonvulsants, oral contraceptives
Increased loss	Hemodialysis
Increased requirement	Pregnancy, infancy, disseminated cancer, markedly increased hematopoiesis
Impaired utilization	Folate antagonists (methotrexate, trimethoprim)

Clinical features:

Megaloblastic anemia (identical hematology to B12 deficiency)
GI mucosal changes: sore tongue, glossitis
NO neurologic manifestations (key distinguishing feature from B12 deficiency)

Diagnosis: ↓ serum folate, ↓ RBC folate, ↑ serum homocysteine, normal methylmalonate (distinguishes from B12 deficiency).

Critical: Folate supplementation corrects the anemia of B12 deficiency but does NOT prevent — and may worsen — the neurologic damage. Always exclude B12 deficiency before starting folate therapy.

6. Vitamin B12 (Cobalamin) Deficiency Anemia

Sources: Animal products (meat, fish, dairy, eggs). Heat-stable. Also synthesised by gut flora.

Body stores: Liver stores 2–5 mg — sufficient for 5–20 years. Clinical presentation therefore follows years of unrecognised malabsorption.

Absorption pathway:

Fig. 10.12 — Vitamin B12 absorption: dietary B12 → stomach (freed by pepsin, binds haptocorrin) → duodenum (pancreatic proteases release B12, binds intrinsic factor) → terminal ileum (IF-B12 complex binds cubilin receptor on ileal enterocytes) → absorbed, bound to transcobalamin II → delivered to liver and bone marrow. (Robbins Basic Pathology)

Causes of B12 Deficiency

Cause	Mechanism
Pernicious anemia (most common)	Autoimmune atrophic gastritis → loss of parietal cells → absent intrinsic factor. Serum autoantibodies to IF (diagnostic but not primary pathogen).
Gastrectomy	Loss of IF-producing cells
Ileal resection / Crohn disease / Whipple disease	Loss of IF-B12 absorbing cells
Blind loop / diverticulosis	Bacterial overgrowth → competitive uptake
Fish tapeworm (Diphyllobothrium)	Competitive parasitic uptake
Gastric atrophy / achlorhydria	Cannot release B12 from food-bound form (especially elderly)
Strict veganism	Only cause of dietary B12 deficiency

Why B12 Deficiency Causes Neurologic Damage (and Folate Deficiency Does Not)

Vitamin B12 has two unique metabolic roles:

Methylation of homocysteine → methionine (requires methylcobalamin; regenerates tetrahydrofolate → thymidine synthesis)
Isomerisation of methylmalonyl-CoA → succinyl-CoA (requires adenosylcobalamin)

Folate deficiency only affects role #1 (thymidine synthesis). B12 deficiency affects both. Defective methylmalonyl-CoA conversion accumulates methylmalonic acid — which disrupts myelin synthesis in neuronal cells.

Neurologic lesion — Subacute Combined Degeneration (SCD):

Demyelination of posterior columns (dorsal) — loss of vibration sense, proprioception
Demyelination of lateral columns (corticospinal tracts) — spastic weakness, hyperreflexia
Peripheral neuropathy — symmetric tingling, numbness, burning in feet/hands
Neurologic damage may be irreversible even after B12 treatment

Clinical Features of Pernicious Anemia

Feature	Detail
Anemia	Pallor, fatigue, dyspnea, palpitations
Mild jaundice	Ineffective erythropoiesis → intramedullar haemolysis
Glossitis	"Beefy red tongue" — megaloblastic changes in oral mucosa
Neurologic	SCD: symmetric paraesthesias → unsteady gait → loss of position sense
Gastric	Autoimmune atrophic gastritis; increased risk of gastric carcinoma

Diagnosis of B12 Deficiency

Finding	Result
Serum B12	↓
Serum folate	Normal or ↑
Serum homocysteine	↑
Serum methylmalonate	↑ (unique to B12 deficiency)
Blood smear	Macro-ovalocytes, hypersegmented neutrophils
Bone marrow	Hypercellular, megaloblastic changes
Anti-intrinsic factor antibodies	Present in pernicious anemia (specific)

Response to treatment: Reticulocytosis in 2–3 days after parenteral B12; anemia resolves over weeks. Neurologic deficits often persist or are only partially reversible.

Differentiating B12 from Folate Deficiency

Feature	B12 Deficiency	Folate Deficiency
Serum B12	↓	Normal
Serum folate	Normal or ↑	↓
RBC folate	Normal	↓
Homocysteine	↑	↑
Methylmalonate	↑	Normal
Neurologic deficits	YES (SCD)	NO
Onset	Slow (years)	Faster (months)

Non-Megaloblastic Macrocytosis

Macrocytic anemia without hypersegmented neutrophils or megaloblastic marrow changes. Mechanisms differ:

Cause	Mechanism
Liver disease / alcoholism	Lipid membrane abnormalities → ↑ RBC membrane surface area → macrocytes (also folate deficiency component)
Hypothyroidism	Slowed RBC maturation
Drugs (hydroxyurea, AZT, azathioprine)	Inhibit DNA synthesis but without classic megaloblastic morphology
Reticulocytosis	Reticulocytes are larger → MCV rises after hemolysis/hemorrhage treatment
MDS	Dyserythropoiesis

Master Summary Table

Feature	IDA	ACD	Thalassemia Minor	Sideroblastic	Folate Def	B12 Def
MCV	↓	Normal/↓	↓	↓ (inherited); variable (acquired)	↑	↑
Serum iron	↓	↓	Normal	↑	Normal	Normal
TIBC	↑	↓	Normal	Normal	Normal	Normal
Ferritin	↓	↑	Normal/↑	↑	Normal	Normal
Transferrin sat	↓	↓	Normal	↑	Normal	Normal
Homocysteine	—	—	—	—	↑	↑
Methylmalonate	—	—	—	—	Normal	↑
Smear hallmark	Microcytic, hypochromic	Mild hypo/normo	Target cells, microcytic	Dimorphic, ring sideroblasts on BM	Macro-ovalocytes, hyperseg PMN	Macro-ovalocytes, hyperseg PMN
Neuro deficits	No	No	No	No (unless Cu deficiency)	No	YES (SCD)
BM finding	↑ cellularity, no iron stores	↑ iron in macrophages	Hyperplastic erythropoiesis	Ringed sideroblasts	Megaloblastic	Megaloblastic

Sources: Robbins & Kumar Basic Pathology (ISBN 9780323790185), Ch. 10, pp. 393–397; Robbins, Cotran & Kumar Pathologic Basis of Disease (ISBN 9780443264528), Ch. 14, pp. 608–616; Goldman-Cecil Medicine, Ch. 145.

This is a shared conversation. Sign in to Orris to start your own chat.